AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition

AbbVie has agreed to help finance a KRAS inhibitor from Kestrel Therapeutics in a deal that could hit up to $1.45 billion in value and end with AbbVie buying the company outright.

By FierceBiotech · May 1, 2026 · via FierceBiotech

AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.